Connection

BING Z CARTER to Cell Line, Tumor

This is a "connection" page, showing publications BING Z CARTER has written about Cell Line, Tumor.
Connection Strength

0.806
  1. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023 09 21; 142(12):1056-1070.
    View in: PubMed
    Score: 0.076
  2. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023 04 24; 13(1):57.
    View in: PubMed
    Score: 0.074
  3. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Mol Cancer Ther. 2022 06 01; 21(6):879-889.
    View in: PubMed
    Score: 0.069
  4. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022 01 01; 107(1):58-76.
    View in: PubMed
    Score: 0.067
  5. Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429.
    View in: PubMed
    Score: 0.052
  6. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017 06; 16(6):1133-1144.
    View in: PubMed
    Score: 0.048
  7. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leuk Res. 2013 Aug; 37(8):974-9.
    View in: PubMed
    Score: 0.037
  8. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011 Jan 20; 117(3):780-7.
    View in: PubMed
    Score: 0.031
  9. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood. 2010 Jan 14; 115(2):306-14.
    View in: PubMed
    Score: 0.029
  10. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009 Sep; 8(9):2509-16.
    View in: PubMed
    Score: 0.029
  11. Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma. 2007 Apr; 48(4):774-85.
    View in: PubMed
    Score: 0.024
  12. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006 Oct; 5(19):2223-9.
    View in: PubMed
    Score: 0.023
  13. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15; 108(2):630-7.
    View in: PubMed
    Score: 0.023
  14. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006 Feb 15; 107(4):1555-63.
    View in: PubMed
    Score: 0.022
  15. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023 12; 9(48):eadh1436.
    View in: PubMed
    Score: 0.019
  16. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Discov. 2023 07 07; 13(7):1656-1677.
    View in: PubMed
    Score: 0.019
  17. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 06 01; 107(6):1311-1322.
    View in: PubMed
    Score: 0.017
  18. Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. Clin Lymphoma Myeloma Leuk. 2022 09; 22(9):652-658.
    View in: PubMed
    Score: 0.017
  19. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. J Transl Med. 2021 03 21; 19(1):117.
    View in: PubMed
    Score: 0.016
  20. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death Dis. 2020 07 22; 11(7):555.
    View in: PubMed
    Score: 0.015
  21. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomed Pharmacother. 2020 Sep; 129:110390.
    View in: PubMed
    Score: 0.015
  22. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 11 26; 3(22):3661-3673.
    View in: PubMed
    Score: 0.015
  23. miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways. Cell Death Dis. 2016 09 22; 7(9):e2371.
    View in: PubMed
    Score: 0.012
  24. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget. 2015 Oct 20; 6(32):33612-22.
    View in: PubMed
    Score: 0.011
  25. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget. 2014 Oct 15; 5(19):9118-32.
    View in: PubMed
    Score: 0.010
  26. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol. 2014 May; 73(5):961-74.
    View in: PubMed
    Score: 0.010
  27. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 2010 Nov 01; 116(21):4980-90.
    View in: PubMed
    Score: 0.008
  28. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):852-9.
    View in: PubMed
    Score: 0.006
  29. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 2007 Mar 01; 109(5):2121-9.
    View in: PubMed
    Score: 0.006
  30. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst. 2006 Aug 02; 98(15):1068-77.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.